Morphologic and molecular heterogeneity in imatinib-resistant GIST

被引：0
|
作者：
Liegl, B.
Kepten, I.
Donsky, R.
Fletcher, C. D. M.
Corless, C. L.
Fletcher, J. A.
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Med Univ Graz, Graz, Austria
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
LABORATORY INVESTIGATION | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
51
引用
收藏
页码：14A / 14A
页数：1
相关论文
共 50 条
  • [31] Dasatinib is active in imatinib-resistant and imatinib-intolerant patients with CML
    Nature Clinical Practice Oncology, 2007, 4 (6): : 328 - 328
  • [32] Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status.
    Heinrich, M. C.
    Maki, R. G.
    Corless, C. L.
    Antonescu, C. R.
    Fletcher, J. A.
    Fletcher, C. D.
    Huang, X.
    Baum, C. M.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 520S - 520S
  • [33] A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)
    Dumez, H.
    Reichard, P.
    Blay, J. Y.
    Schoeffski, P.
    Morgan, J. A.
    Ray-Coquard, I. L.
    Hollaender, N.
    Jappe, A.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] IPI504, a novel HSP90 inhibitor, causes inhibition and degradation of KIT in imatinib-resistant GIST: Rationale for therapeutic targeting in GIST.
    Bauer, S
    Yu, L
    Read, M
    Normant, E
    Demetri, GD
    Fletcher, JA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9111S - 9111S
  • [35] Activity of AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): Preclinical rationale and early clinical results with imatinib-resistant GIST.
    Demetri, GD
    Bauer, S
    Dileo, P
    van den Abbeele, A
    George, S
    Morgan, J
    Veronese, L
    Alland, L
    Massimini, G
    Salesi, J
    Quigley, MT
    Pokela, J
    Denise, C
    Manley, P
    Fletcher, JA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9030S - 9030S
  • [36] Abscopal Effect of Radiotherapy in Imatinib-resistant Dermatofibrosarcoma Protuberans
    Agyeman, Mervin B.
    Vanderpuye, Verna D.
    Yarney, Joel
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (01)
  • [37] Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CML
    Zhu, Guang-rong
    Ji, Ou
    Ji, Jian-min
    Zhang, Ya-cheng
    Wu, Yu
    Yu, Hui
    Jiang, Peng-Jun
    Shen, Qun
    ACTA HAEMATOLOGICA, 2012, 127 (03) : 152 - 155
  • [38] Treatment options in imatinib-resistant chronic myelogenous leukemia
    Marshall, Helen M.
    Hammond, Julia M.
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (02) : 259 - 264
  • [39] Novel effect of azithromycin in imatinib-resistant CML cells
    Ozkan, T.
    Hekmatshoar, Y.
    Karabay, A. Z.
    Sunguroglu, A.
    FEBS OPEN BIO, 2018, 8 : 346 - 346
  • [40] Management of imatinib-resistant patients with chronic myeloid leukemia
    Bhamidipati, Pavan Kumar
    Kantarjian, Hagop
    Cortes, Jorge
    Cornelison, A. Megan
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2013, 4 (02) : 103 - 117
12345